| 1 | A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients | 5.3 | 5 | Citations (PDF) |
| 2 | Impact of COVID-19 on the Stage and Treatment of Endometrial Cancer: A Cancer Registry Analysis from an Italian Comprehensive Cancer Center | 3.8 | 1 | Citations (PDF) |
| 3 | Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer | 4.2 | 21 | Citations (PDF) |
| 4 | Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications | 1.8 | 5 | Citations (PDF) |
| 5 | Impact of the COVID-19 Pandemic on Prostate Cancer Diagnosis, Staging, and Treatment: A Population-Based Study in Northern Italy | 2.8 | 8 | Citations (PDF) |
| 6 | Trends in cervical cancer: A decade‑long analysis of incidence, survival and demographic disparities in a Northern Italian province | 1.2 | 5 | Citations (PDF) |
| 7 | A Population-Based Analysis of the Cancer Incidence in Individuals under 50 in a Northern Italian Province: Focusing on Regional Disparities and Public Health Implications | 2.9 | 2 | Citations (PDF) |
| 8 | A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growthBlood, 2023, 141, 391-405 | 5.0 | 33 | Citations (PDF) |
| 9 | The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer | 2.6 | 73 | Citations (PDF) |
| 10 | Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020 | 2.6 | 5 | Citations (PDF) |
| 11 | Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy | 2.6 | 14 | Citations (PDF) |
| 12 | Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients | 1.8 | 9 | Citations (PDF) |
| 13 | LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells | 2.1 | 9 | Citations (PDF) |
| 14 | Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study | 2.3 | 3 | Citations (PDF) |
| 15 | Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity | 3.4 | 41 | Citations (PDF) |
| 16 | MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort | 5.0 | 11 | Citations (PDF) |
| 17 | Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study | 3.8 | 8 | Citations (PDF) |
| 18 | Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements | 2.6 | 10 | Citations (PDF) |
| 19 | Molecular Modelling of NONO and SFPQ Dimerization Process and RNA Recognition Mechanism | 4.4 | 16 | Citations (PDF) |
| 20 | Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma | 2.4 | 3 | Citations (PDF) |
| 21 | Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88Blood, 2021, 137, 2495-2508 | 5.0 | 10 | Citations (PDF) |
| 22 | What Is New in the Treatment of Smoldering Multiple Myeloma? | 2.5 | 9 | Citations (PDF) |
| 23 | Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases | 1.8 | 8 | Citations (PDF) |
| 24 | Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients | 6.3 | 6 | Citations (PDF) |
| 25 | Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs | 2.5 | 8 | Citations (PDF) |
| 26 | The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma | 3.8 | 35 | Citations (PDF) |
| 27 | Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol | 1.8 | 8 | Citations (PDF) |
| 28 | Genomic Instability in Multiple Myeloma: A “Non-Coding RNA” Perspective | 3.8 | 13 | Citations (PDF) |
| 29 | Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities | 3.8 | 39 | Citations (PDF) |
| 30 | Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activityBlood, 2021, 138, 1705-1720 | 5.0 | 21 | Citations (PDF) |
| 31 | Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings? | 3.8 | 4 | Citations (PDF) |
| 32 | Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma | 6.9 | 16 | Citations (PDF) |
| 33 | Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia | 2.6 | 11 | Citations (PDF) |
| 34 | miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma | 3.8 | 23 | Citations (PDF) |
| 35 | Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma | 6.8 | 23 | Citations (PDF) |
| 36 | Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity | 3.8 | 10 | Citations (PDF) |
| 37 | Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? | 4.6 | 48 | Citations (PDF) |
| 38 | ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape | 4.4 | 19 | Citations (PDF) |
| 39 | Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells | 4.4 | 14 | Citations (PDF) |
| 40 | Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma | 3.8 | 1 | Citations (PDF) |
| 41 | Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma | 3.8 | 51 | Citations (PDF) |
| 42 | Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? | 2.6 | 85 | Citations (PDF) |
| 43 | Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients | 3.4 | 15 | Citations (PDF) |
| 44 | Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology | 2.1 | 14 | Citations (PDF) |
| 45 | Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death | 5.0 | 26 | Citations (PDF) |
| 46 | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab | 5.5 | 9 | Citations (PDF) |
| 47 | Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells | 3.8 | 11 | Citations (PDF) |
| 48 | Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma | 0.4 | 18 | Citations (PDF) |
| 49 | International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaBlood, 2020, 135, 1859-1869 | 5.0 | 130 | Citations (PDF) |
| 50 | Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma | 3.8 | 11 | Citations (PDF) |
| 51 | TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors | 3.9 | 12 | Citations (PDF) |
| 52 | NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome | 2.1 | 16 | Citations (PDF) |
| 53 | Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach | 5.6 | 21 | Citations (PDF) |
| 54 | LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems? | 2.1 | 63 | Citations (PDF) |
| 55 | Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients | 2.1 | 7 | Citations (PDF) |
| 56 | COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death | 8.6 | 20 | Citations (PDF) |
| 57 | The Non-Coding RNA Landscape of Plasma Cell Dyscrasias | 3.8 | 30 | Citations (PDF) |
| 58 | Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma | 3.8 | 8 | Citations (PDF) |
| 59 | Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) | 2.1 | 2 | Citations (PDF) |
| 60 | Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphoma | 6.5 | 20 | Citations (PDF) |
| 61 | Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma | 3.8 | 40 | Citations (PDF) |
| 62 | Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing | 5.5 | 12 | Citations (PDF) |
| 63 | PB1761 CLINICAL IMPACT OF NPM1 MUTATION SUBTYPES IN A MONOCENTRIC COHORT OF ACUTE MYELOID LEUKEMIA | 0.4 | 1 | Citations (PDF) |
| 64 | Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target? | 7.0 | 33 | Citations (PDF) |
| 65 | IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignanciesBlood, 2019, 133, 156-167 | 5.0 | 59 | Citations (PDF) |
| 66 | IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia | 7.7 | 13 | Citations (PDF) |
| 67 | Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma | 7.7 | 101 | Citations (PDF) |
| 68 | Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity | 7.7 | 249 | Citations (PDF) |
| 69 | Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab | 7.7 | 9 | Citations (PDF) |
| 70 | Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence | 12.5 | 16 | Citations (PDF) |
| 71 | The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma | 5.5 | 21 | Citations (PDF) |
| 72 | Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphomaBlood, 2018, 131, 2413-2425 | 5.0 | 316 | Citations (PDF) |
| 73 | Pathogenicity of In Vivo Generated Intestinal Th17 Lymphocytes is IFNγ Dependent | 1.3 | 23 | Citations (PDF) |
| 74 | Comparison between the CLL‐IPI and the Barcelona‐Brno prognostic model: Analysis of 1299 newly diagnosed cases | 6.5 | 21 | Citations (PDF) |
| 75 | Global methylation patterns in primary plasma cell leukemia | 0.7 | 17 | Citations (PDF) |
| 76 | Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment | 1.8 | 10 | Citations (PDF) |
| 77 | Long Non-Coding RNAs in Multiple Myeloma | 2.5 | 26 | Citations (PDF) |
| 78 | Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases | 6.5 | 17 | Citations (PDF) |
| 79 | Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92Blood, 2018, 132, 1050-1063 | 5.0 | 72 | Citations (PDF) |
| 80 | A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma | 3.4 | 40 | Citations (PDF) |
| 81 | miR-22 suppresses DNA ligase III addiction in multiple myeloma | 7.7 | 46 | Citations (PDF) |
| 82 | Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer | 25.2 | 88 | Citations (PDF) |
| 83 | Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy | 7.7 | 35 | Citations (PDF) |
| 84 | Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia | 0.7 | 23 | Citations (PDF) |
| 85 | Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers | 6.8 | 152 | Citations (PDF) |
| 86 | Utilizing next-generation sequencing in the management of multiple myeloma | 3.0 | 30 | Citations (PDF) |
| 87 | Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells | 8.6 | 20 | Citations (PDF) |
| 88 | EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells | 4.0 | 15 | Citations (PDF) |
| 89 | ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma | 33.0 | 154 | Citations (PDF) |
| 90 | Biological and molecular characterization of a rare case of cutaneous Richter syndrome | 2.1 | 4 | Citations (PDF) |
| 91 | Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression | 5.5 | 6 | Citations (PDF) |
| 92 | Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines | 7.7 | 111 | Citations (PDF) |
| 93 | Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening | 2.3 | 32 | Citations (PDF) |
| 94 | In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma | 2.5 | 18 | Citations (PDF) |
| 95 | Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patientsBlood, 2016, 128, 2093-2095 | 5.0 | 60 | Citations (PDF) |
| 96 | Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma | 1.9 | 106 | Citations (PDF) |
| 97 | Primary Plasma Cell Leukemia: Identity Card 2016 | 3.9 | 17 | Citations (PDF) |
| 98 | lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome | 5.5 | 57 | Citations (PDF) |
| 99 | The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients | 6.5 | 79 | Citations (PDF) |
| 100 | Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O‐CLL1‐GISL study | 1.8 | 9 | Citations (PDF) |
| 101 | Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcriptsBlood, 2016, 127, 221-232 | 5.0 | 116 | Citations (PDF) |
| 102 | A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI) | 2.6 | 5 | Citations (PDF) |
| 103 | Primary plasma cell leukemia 2.0: advances in biology and clinical management | 2.0 | 16 | Citations (PDF) |
| 104 | Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo | 7.7 | 34 | Citations (PDF) |
| 105 | miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth | 5.5 | 56 | Citations (PDF) |
| 106 | Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature | 1.9 | 2 | Citations (PDF) |
| 107 | Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? | 1.5 | 17 | Citations (PDF) |
| 108 | Targeting Notch as a Therapeutic Approach for Human Malignancies | 2.4 | 17 | Citations (PDF) |
| 109 | PI3K/AKT signaling inhibits NOTCH1 lysosome‐mediated degradation | 3.0 | 30 | Citations (PDF) |
| 110 | Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine | 4.4 | 25 | Citations (PDF) |
| 111 | Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment | 0.7 | 16 | Citations (PDF) |
| 112 | Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1α chemokine system | 2.6 | 47 | Citations (PDF) |
| 113 | Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo | 7.7 | 120 | Citations (PDF) |
| 114 | Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia | 1.4 | 25 | Citations (PDF) |
| 115 | The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA | 15.5 | 36 | Citations (PDF) |
| 116 | A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients | 7.7 | 33 | Citations (PDF) |
| 117 | Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma AgentBlood, 2015, 126, 3025-3025 | 5.0 | 1 | Citations (PDF) |
| 118 | Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia | 2.3 | 16 | Citations (PDF) |
| 119 | Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell LinesBlood, 2015, 126, 3019-3019 | 5.0 | 0 | Citations (PDF) |
| 120 | A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia PatientsBlood, 2015, 126, 2930-2930 | 5.0 | 0 | Citations (PDF) |
| 121 | The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4Blood, 2015, 126, 5315-5315 | 5.0 | 0 | Citations (PDF) |
| 122 | Next-Generation Sequencing in Multiple Myeloma: Insights into the Molecular Heterogeneity of the Disease | 2.4 | 3 | Citations (PDF) |
| 123 | Long term assessment of intralipotherapy in Madelung’s disease | 0.9 | 10 | Citations (PDF) |
| 124 | A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells | 4.1 | 93 | Citations (PDF) |
| 125 | Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O‐CLL1‐GISL study | 6.5 | 16 | Citations (PDF) |
| 126 | Molecular events underlying interleukin‐6 independence in a subclone of the CMA‐03 multiple myeloma cell line | 3.0 | 6 | Citations (PDF) |
| 127 | Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia | 3.0 | 11 | Citations (PDF) |
| 128 | B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities | 2.1 | 24 | Citations (PDF) |
| 129 | High‐throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications | 2.7 | 59 | Citations (PDF) |
| 130 | Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers | 33.0 | 288 | Citations (PDF) |
| 131 | Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? | 1.4 | 16 | Citations (PDF) |
| 132 | Autoimmune cytopenias in chronic lymphocytic leukemia | 6.5 | 106 | Citations (PDF) |
| 133 | Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia | 3.0 | 45 | Citations (PDF) |
| 134 | microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters | 6.8 | 57 | Citations (PDF) |
| 135 | The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma | 7.7 | 95 | Citations (PDF) |
| 136 | Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing | 3.0 | 20 | Citations (PDF) |
| 137 | Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules | 0.4 | 73 | Citations (PDF) |
| 138 | Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia | 1.7 | 80 | Citations (PDF) |
| 139 | Total body computed tomography scan in the initial work‐up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O‐CLL1‐GISL study | 6.5 | 13 | Citations (PDF) |
| 140 | Genome‐wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles | 6.5 | 67 | Citations (PDF) |
| 141 | Chromosome 2p gain in monoclonal B‐cell lymphocytosis and in early stage chronic lymphocytic leukemia | 6.5 | 29 | Citations (PDF) |
| 142 | B‐cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia | 6.5 | 37 | Citations (PDF) |
| 143 | EGFR through STAT3 modulates ΔN63α expression to sustain tumor‐initiating cell proliferation in squamous cell carcinomas | 4.1 | 26 | Citations (PDF) |
| 144 | The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis | 0.7 | 10 | Citations (PDF) |
| 145 | Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction | 7.7 | 114 | Citations (PDF) |
| 146 | Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia | 6.5 | 20 | Citations (PDF) |
| 147 | Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL) | 0.7 | 12 | Citations (PDF) |
| 148 | Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma | 3.0 | 76 | Citations (PDF) |
| 149 | Improved risk stratification in myeloma using a microRNA‐based classifier | 2.7 | 55 | Citations (PDF) |
| 150 | Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features | 6.8 | 64 | Citations (PDF) |
| 151 | Targeting miR-21 Inhibits
In Vitro
and
In Vivo
Multiple Myeloma Cell Growth | 6.8 | 219 | Citations (PDF) |
| 152 | Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome | 6.8 | 53 | Citations (PDF) |
| 153 | External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia | 4.0 | 18 | Citations (PDF) |
| 154 | Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia | 6.8 | 92 | Citations (PDF) |
| 155 | Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia | 7.7 | 92 | Citations (PDF) |
| 156 | Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial | 7.7 | 58 | Citations (PDF) |
| 157 | MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL)Blood, 2013, 122, 4172-4172 | 5.0 | 3 | Citations (PDF) |
| 158 | Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma:
In Vitro
and
In Vivo
Evidence | 6.8 | 231 | Citations (PDF) |
| 159 | Prognostic factors in CLL | 0.0 | 5 | Citations (PDF) |
| 160 | Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines? | 7.7 | 21 | Citations (PDF) |
| 161 | miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 | 8.5 | 147 | Citations (PDF) |
| 162 | Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphomaBlood, 2012, 120, 1274-1281 | 5.0 | 114 | Citations (PDF) |
| 163 | The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells | 0.4 | 39 | Citations (PDF) |
| 164 | Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia | 1.4 | 12 | Citations (PDF) |
| 165 | The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma | 5.5 | 76 | Citations (PDF) |
| 166 | Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myelomaBlood, 2012, 120, 5002-5013 | 5.0 | 140 | Citations (PDF) |
| 167 | Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation | 7.7 | 135 | Citations (PDF) |
| 168 | Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors | 6.8 | 33 | Citations (PDF) |
| 169 | Primary plasma cell leukemia in the era of new drugs: Has something changed? | 5.0 | 19 | Citations (PDF) |
| 170 | Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells | 7.7 | 55 | Citations (PDF) |
| 171 | The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial–mesenchymal transition and invasive properties of prostate cancer | 6.5 | 150 | Citations (PDF) |
| 172 | Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell LeukemiaBlood, 2012, 120, 729-729 | 5.0 | 1 | Citations (PDF) |
| 173 | B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic LeukemiaBlood, 2012, 120, 1780-1780 | 5.0 | 0 | Citations (PDF) |
| 174 | Intraclonal Cell Expansion and Selection Driven by B Cell Receptor in Chronic Lymphocytic Leukemia | 5.6 | 12 | Citations (PDF) |
| 175 | Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia | 2.3 | 38 | Citations (PDF) |
| 176 | Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myelomaBlood, 2011, 117, 553-562 | 5.0 | 242 | Citations (PDF) |
| 177 | The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemiaBlood, 2011, 118, 6353-6361 | 5.0 | 48 | Citations (PDF) |
| 178 | The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide | 0.4 | 8 | Citations (PDF) |
| 179 | Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations | 6.5 | 9 | Citations (PDF) |
| 180 | Multiplex ligation‐dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in Chronic lymphocytic leukemia: A comparative study | 3.0 | 24 | Citations (PDF) |
| 181 | Genomic profiling of enzastaurin-treated B cell lymphoma RL cells | 2.1 | 4 | Citations (PDF) |
| 182 | Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines | 0.7 | 7 | Citations (PDF) |
| 183 | Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects | 4.7 | 12 | Citations (PDF) |
| 184 | Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia | 3.0 | 60 | Citations (PDF) |
| 185 | The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma | 6.8 | 69 | Citations (PDF) |
| 186 | Impact of Host Genes and Strand Selection on miRNA and miRNA* Expression | 2.3 | 38 | Citations (PDF) |
| 187 | Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Patients in Early Stage Disease,Blood, 2011, 118, 3890-3890 | 5.0 | 7 | Citations (PDF) |
| 188 | Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell ReceptorsBlood, 2011, 118, 2847-2847 | 5.0 | 1 | Citations (PDF) |
| 189 | Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease | 0.4 | 61 | Citations (PDF) |
| 190 | The clinical and biological features of a series of immunophenotypic variant of B‐CLL | 1.8 | 14 | Citations (PDF) |
| 191 | Should pre-transfusion screening RBC panels contain Wr(a+) cells? | 0.9 | 4 | Citations (PDF) |
| 192 | Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL | 2.7 | 17 | Citations (PDF) |
| 193 | Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients | 7.7 | 8 | Citations (PDF) |
| 194 | Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion | 6.8 | 53 | Citations (PDF) |
| 195 | Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells | 7.7 | 109 | Citations (PDF) |
| 196 | Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches | 1.4 | 49 | Citations (PDF) |
| 197 | HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients | 7.7 | 45 | Citations (PDF) |
| 198 | Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma | 6.8 | 100 | Citations (PDF) |
| 199 | Differential repetitive DNA methylation in multiple myeloma molecular subgroups | 2.8 | 106 | Citations (PDF) |
| 200 | Serum level of CD26 predicts time to first treatment in early B‐chronic lymphocytic leukemia | 1.8 | 11 | Citations (PDF) |
| 201 | Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting | 5.1 | 9 | Citations (PDF) |
| 202 | Identification of primary MAFB target genes in multiple myeloma | 0.4 | 49 | Citations (PDF) |
| 203 | Molecular targeting of the PKC‐β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression | 2.1 | 20 | Citations (PDF) |
| 204 | CD26 expression in mature B‐cell neoplasia: its possible role as a new prognostic marker in B‐CLL | 2.1 | 49 | Citations (PDF) |
| 205 | Gene array profile identifies collagen type XV as a novel human osteoblast‐secreted matrix protein | 4.1 | 30 | Citations (PDF) |
| 206 | Integrative high‐resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles | 3.0 | 60 | Citations (PDF) |
| 207 | A SNP microarray and FISH‐based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect | 3.0 | 147 | Citations (PDF) |
| 208 | Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia | 2.7 | 50 | Citations (PDF) |
| 209 | Response of AIHA to high dose intravenous immunoglobulins in a patient with ovarian teratoma | 3.0 | 2 | Citations (PDF) |
| 210 | Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study | 7.7 | 37 | Citations (PDF) |
| 211 | International Myeloma Working Group molecular classification of multiple myeloma: spotlight review | 7.7 | 833 | Citations (PDF) |
| 212 | Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myelomaBlood, 2009, 114, e20-e26 | 5.0 | 228 | Citations (PDF) |
| 213 | Biological and Molecular Characterization by Integrative Genomics Approach of CMA-03/06, a Newly Established Interleukin-6 Independent Variant of the CMA-03 Human Myeloma Cell Line.Blood, 2009, 114, 1814-1814 | 5.0 | 0 | Citations (PDF) |
| 214 | Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia | 1.5 | 13 | Citations (PDF) |
| 215 | An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma | 1.7 | 106 | Citations (PDF) |
| 216 | Molecular and transcriptional characterization of 17p loss in B‐cell chronic lymphocytic leukemia | 3.0 | 60 | Citations (PDF) |
| 217 | The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods | 1.4 | 7 | Citations (PDF) |
| 218 | Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia | 1.4 | 4 | Citations (PDF) |
| 219 | The oral protein-kinase Cβinhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines | 1.4 | 38 | Citations (PDF) |
| 220 | CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomibBlood, 2008, 111, 2765-2775 | 5.0 | 254 | Citations (PDF) |
| 221 | Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia.Blood, 2008, 112, 1062-1062 | 5.0 | 0 | Citations (PDF) |
| 222 | HOXB7 Overexpression in Mesenchymal Cells Stimulates the Production of Pro-Angiogenic Molecules: Potential Role in Multiple Myeloma Associated AngiogenesisBlood, 2008, 112, 2743-2743 | 5.0 | 1 | Citations (PDF) |
| 223 | Repetitive DNA Hypomethylation in Multiple MyelomaBlood, 2008, 112, 2703-2703 | 5.0 | 16 | Citations (PDF) |
| 224 | Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell LinesBlood, 2008, 112, 4978-4978 | 5.0 | 0 | Citations (PDF) |
| 225 | The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 α (HIF-1α) activity: involvement in myeloma-induced angiogenesisBlood, 2007, 110, 4464-4475 | 5.0 | 120 | Citations (PDF) |
| 226 | Oct-4 Expression in Adult Human Differentiated Cells Challenges Its Role as a Pure Stem Cell Marker | 3.2 | 159 | Citations (PDF) |
| 227 | Relevance ofRas gene mutations in the context of the molecular heterogeneity of multiple myeloma | 2.1 | 8 | Citations (PDF) |
| 228 | Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease | 3.0 | 64 | Citations (PDF) |
| 229 | Molecular and transcriptional characterization of the novel 17p11.2‐p12 amplicon in multiple myeloma | 3.0 | 22 | Citations (PDF) |
| 230 | Transcriptional features of multiple myeloma patients with chromosome 1q gain | 7.7 | 49 | Citations (PDF) |
| 231 | The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells | 7.7 | 105 | Citations (PDF) |
| 232 | Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma | 2.7 | 67 | Citations (PDF) |
| 233 | Effect of Dioxin (TCDD) on Gene Transcription of Human CD34+ Hematopoietic Cells.Blood, 2007, 110, 4033-4033 | 5.0 | 0 | Citations (PDF) |
| 234 | Sphingosine Kinase 1 as a Potential Target To Inhibit Proliferation of Myeloid Leukemia Cells.Blood, 2007, 110, 4196-4196 | 5.0 | 0 | Citations (PDF) |
| 235 | Molecular and Transcriptional Characterization of the Novel 17p11.2-p12 Chromosome Amplification in Multiple Myeloma.Blood, 2007, 110, 2486-2486 | 5.0 | 0 | Citations (PDF) |
| 236 | Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles.Blood, 2007, 110, 2482-2482 | 5.0 | 0 | Citations (PDF) |
| 237 | IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia | 2.7 | 21 | Citations (PDF) |
| 238 | The prevalence and clinical implications of c-kit expression in plasma cell myeloma | 3.6 | 14 | Citations (PDF) |
| 239 | Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes | 10.6 | 145 | Citations (PDF) |
| 240 | Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma | 2.7 | 25 | Citations (PDF) |
| 241 | Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma | 6.5 | 123 | Citations (PDF) |
| 242 | Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses | 3.0 | 50 | Citations (PDF) |
| 243 | The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence ofp63 gene amplification | 4.9 | 41 | Citations (PDF) |
| 244 | Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma | 16.9 | 128 | Citations (PDF) |
| 245 | Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations | 16.9 | 125 | Citations (PDF) |
| 246 | Association Between p53 Gene Mutations and Tobacco and Alcohol Exposure in Laryngeal Squamous Cell Carcinoma | 1.8 | 16 | Citations (PDF) |
| 247 | Identification of a novel IGH-MMSET
fusion transcript in a human myeloma cell line with the t(4;14)(p16·3;q32) chromosomal translocation | 2.7 | 6 | Citations (PDF) |
| 248 | Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation orcyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index | 4.3 | 17 | Citations (PDF) |
| 249 | Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1 | 3.2 | 6 | Citations (PDF) |
| 250 | Heterogeneous pattern of chromosomal breakpoints involving theMYC locus in multiple myeloma | 3.0 | 32 | Citations (PDF) |
| 251 | Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation | 4.9 | 8 | Citations (PDF) |
| 252 | Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias | 7.7 | 22 | Citations (PDF) |
| 253 | Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation | 4.8 | 22 | Citations (PDF) |
| 254 | Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation | 2.3 | 20 | Citations (PDF) |
| 255 | Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantationBlood, 2003, 102, 1588-1594 | 5.0 | 114 | Citations (PDF) |
| 256 | A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14) | 7.7 | 3 | Citations (PDF) |
| 257 | Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients | 2.7 | 90 | Citations (PDF) |
| 258 | p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity | 3.2 | 40 | Citations (PDF) |
| 259 | Translocation t(4;14)(p16.3;q32) Is a Recurrent Genetic Lesion in Primary Amyloidosis | 3.4 | 31 | Citations (PDF) |
| 260 | IRTA1 and IRTA2, Novel Immunoglobulin Superfamily Receptors Expressed in B Cells and Involved in Chromosome 1q21 Abnormalities in B Cell Malignancy | 22.6 | 192 | Citations (PDF) |
| 261 | Analysis of FGFR3
gene mutations in multiple myeloma patients with t(4;14) | 2.7 | 60 | Citations (PDF) |
| 262 | Clinical relevance of microvessel density in laryngeal squamous cell carcinomas | 4.3 | 27 | Citations (PDF) |
| 263 | Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple myeloma cell line | 7.7 | 4 | Citations (PDF) |
| 264 | Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations | 6.5 | 103 | Citations (PDF) |
| 265 | Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells | 9.3 | 852 | Citations (PDF) |
| 266 | Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas | 7.7 | 22 | Citations (PDF) |
| 267 | BCL10 gene mutations rarely occur in lymphoid malignancies | 7.7 | 22 | Citations (PDF) |
| 268 | Immunohistochemical Analysis of Cyclin D1 Shows Deregulated Expression in Multiple Myeloma with the t(11;14) | 3.4 | 76 | Citations (PDF) |
| 269 | Clinical Relevance of Expression of the CIP/KIP Cell-Cycle Inhibitors p21 and p27 in Laryngeal Cancer | 16.9 | 78 | Citations (PDF) |
| 270 | Detection of t(4;14)(p16.3;q32) Chromosomal Translocation in Multiple Myeloma by Double-Color Fluorescent In Situ Hybridization | 5.0 | 58 | Citations (PDF) |
| 271 | Molecular Analysis of 11q13 Breakpoints in Multiple MyelomaBlood, 1999, 93, 1330-1337 | 5.0 | 82 | Citations (PDF) |
| 272 | Trophoblast giant cells express NF-?B2 during early mouse development | 3.3 | 9 | Citations (PDF) |
| 273 | EFA6, a sec7 domain-containing exchange factor for ARF6, coordinates membrane recycling and actin cytoskeleton organization | 7.3 | 272 | Citations (PDF) |
| 274 | Analysis of BCL-10 gene mutations in ovarian cancer cell lines | 9.9 | 3 | Citations (PDF) |
| 275 | Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study | 9.9 | 38 | Citations (PDF) |
| 276 | Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma 1998, 79, 263-268 | | 46 | Citations (PDF) |
| 277 | Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow | 1.5 | 26 | Citations (PDF) |
| 278 | BCL-6 mutations in normal germinal center B cells: Evidence of somatic hypermutation acting outside Ig loci | 7.5 | 508 | Citations (PDF) |
| 279 | Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa | 9.9 | 74 | Citations (PDF) |
| 280 | FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple MyelomaBlood, 1998, 92, 2987-2989 | 5.0 | 36 | Citations (PDF) |
| 281 | EHT, a New Member of the MTG8/ETO Gene Family, Maps on 20q11 Region and Is Deleted in Acute Myeloid LeukemiasBlood, 1998, 92, 3481-3484 | 5.0 | 18 | Citations (PDF) |
| 282 | Identification of a Novel Gene,PSD,Adjacent toNFKB2/lyt-10,Which Contains Sec7 and Pleckstrin-Homology Domains | 2.8 | 27 | Citations (PDF) |
| 283 | A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 GeneBlood, 1997, 90, 4062-4070 | 5.0 | 202 | Citations (PDF) |
| 284 | Identification of a tumor-associated mutant form of the NF-κB RelA gene with reduced DNA-binding and transactivating activities | 6.5 | 37 | Citations (PDF) |
| 285 | Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts | 6.5 | 42 | Citations (PDF) |
| 286 | Molecular and immunohistochemical analysis of thebcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas 1997, 79, 1114-1121 | | 52 | Citations (PDF) |
| 287 | The Involvement of the Candidate Proto-Oncogene NFKB2/
lyt
-10 in Lymphoid Malignancies | 1.4 | 37 | Citations (PDF) |
| 288 | p53 tumour suppressor gene and RAS oncogenes: molecular analysis in the chronic and leukaemic phases of essential thrombocythaemia | 2.7 | 13 | Citations (PDF) |
| 289 | p53 and cyclin D1 protein expression in glottic laryngeal squamous cell carcinomas involving the anterior commissure (pT1bN0M0) | 3.8 | 1 | Citations (PDF) |
| 290 | Multiple genetic lesions in laryngeal squamous cell carcinomas | 4.0 | 32 | Citations (PDF) |
| 291 | Structural and functional characterization of the promoter regions of the NFKB2 gene | 15.5 | 87 | Citations (PDF) |
| 292 | Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin | 5.0 | 64 | Citations (PDF) |
| 293 | Analysis of p53 gene mutations in acute myeloid leukemia | 6.5 | 36 | Citations (PDF) |
| 294 | Analysis of p53 and ras gene mutations in hepatocellular carcinoma in Italy | 1.3 | 1 | Citations (PDF) |
| 295 | Frequency of RAS and p53 Mutations in Acute Promyelocytic Leukemias | 1.4 | 31 | Citations (PDF) |
| 296 | B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50Cell, 1991, 67, 1075-1087 | 33.6 | 432 | Citations (PDF) |
| 297 | Analysis of tumor-specific immunoglobulin gene rearrangement in peripheral blood B-cells of multiple myeloma patients | 6.5 | 12 | Citations (PDF) |
| 298 | p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. | 7.5 | 830 | Citations (PDF) |
| 299 | Lymphomatoid granulomatosis in the acquired immunodeficiency syndrome. Evidence of Epstein-Barr virus infection and B-cell clonal selection withoutmyc rearrangement | 4.0 | 40 | Citations (PDF) |
| 300 | Ras oncogene mutation in multiple myeloma. | 9.3 | 167 | Citations (PDF) |
| 301 | Immunologic and molecular evaluation of residual disease in b-cell chronic lymphocytic leukemia patients in clinical remission phase | 4.0 | 16 | Citations (PDF) |
| 302 | Preoperative staging of primary breast cancer.A multicentric study | 4.0 | 73 | Citations (PDF) |
| 303 | Analysis of RAS oncogene mutations in human lymphoid malignancies. | 7.5 | 192 | Citations (PDF) |
| 304 | Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. | 7.5 | 230 | Citations (PDF) |
| 305 | Mechanism of Activation and Biological Role of the c-myc Oncogene in B-cell Lymphomagenesis | 4.0 | 25 | Citations (PDF) |
| 306 | Arrangements and Rearrangements of the Human T-cell Receptor Gamma Gene | 4.0 | 0 | Citations (PDF) |
| 307 | Genotypic Monoclonality in Immunophenotypically Polyclonal Orbital Lymphoid Tumors | 7.9 | 73 | Citations (PDF) |
| 308 | Germ‐line configuration of the T‐cell receptor beta‐chain gene in B‐cell chronic lymphoproliferative disorders which co‐express T‐cell antigens | 1.8 | 10 | Citations (PDF) |
| 309 | Immunoglobulin and T-cell receptor beta-chain gene rearrangement analysis of Hodgkin's disease: implications for lineage determination and differential diagnosis. | 7.5 | 153 | Citations (PDF) |
| 310 | Meeting report on recent advances on T-Lymphocytes in normal and leukemia patients | 0.0 | 0 | Citations (PDF) |
| 311 | Functional and multimarker analysis of T‐cell chronic lymphocytic leukaemia | 0.0 | 11 | Citations (PDF) |
| 312 | The accuracy of administrative data in identifying pulmonary metastases: a population-based study in Northern Italy | 2.0 | 0 | Citations (PDF) |
| 313 | Incidence and survival of vulvar and vaginal cancers in a province of Northern Italy: a population-based study | 0.7 | 0 | Citations (PDF) |
